brain atrophy

Blood levels of MIF protein may predict brain atrophy with PPMS

Higher blood levels of macrophage migration inhibitory factor (MIF), a molecule involved in inflammation, may predict a faster rate of brain shrinkage, or atrophy, in people with primary progressive multiple sclerosis (PPMS). That’s according to a new analysis of data from the SPRINT-MS Phase 2 trial (NCT01982942) that…

‘Time Is Brain’: Managing Brain Atrophy With MS

This is one of my “nobody ever told me that” columns. I was amazed when I read a comment from one of my “MS Wire” readers recently about brain shrinkage. “I’ve had MS since 2011. I had no idea about brain shrinkage,” she wrote. I guess I shouldn’t have…

MS Patients Help Steer Guidelines for Talks About Brain Volume Loss

A team of doctors, researchers, and patients has come up with a set of recommendations to help medical professionals in navigating difficult discussions with patients about brain atrophy ā€” or shrinkage ā€” with multiple sclerosis (MS). ā€œOur goal is to minimize misunderstanding and apprehension about brain atrophy, also known…

Longer Breastfeeding May Damage Brain By Delaying DMT Use

Having at least one pregnancy may lower disability scores in women with multiple sclerosis (MS), but breastfeeding for longer than six months may worsen damage to the brain, an observational study in patients has found. Findings support the need for careful pregnancy planning, counseling, and treatment management to ensure…

Novel MRI Marker Better at Predicting MS Progression, Study Reports

A large retrospective study suggests that a magnetic resonance imaging (MRI) marker ā€” called ā€œbrain atrophied T2 lesion volumeā€Ā ā€” could help predict the timing of multiple sclerosis (MS) progression. According to the study, this marker was the only MRI parameter capable of predicting disease progression, compared with other…

Need to Know: Does Brain Matter Matter?

Editor’s note: “Need to Knowā€ is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topicĀ “Grey Matter Atrophy in MS Shown to Follow a Pattern” from July…

Aubagio, Tecfidera Show Comparable Effectiveness in Relapsing MS, Real-world Phase 4 Trial Finds

Aubagio (teriflunomide)Ā seems to be superior to Tecfidera (dimethyl fumarate)Ā in slowingĀ whole brain shrinkage in patients withĀ relapsing multiple sclerosis (MS), a new Phase 4 clinical trial shows. However, Aubagio and Tecfidera have similar beneficial effects in achieving other clinical goals and magnetic resonance imaging (MRI) parameters,…

#ECTRIMS2018 – GNbAC1 Shows Consistent Neuroprotection in RRMS Patients, Phase 2b Study Reports

TreatingĀ relapsing-remitting multiple sclerosis (RRMS) patients with GeNeuroā€™s investigational compound GNbAC1 lessened brain atrophy and lesion load and suggested myelin preservation, according to results of a Phase 2b study. Importantly, monthly intravenous GNbAC1 administration for 48 weeks also had neuroprotective effects in the studyā€™s inactive population, which refers…

GeNeuro to Develop the MS Clinical Program of GNbAC1 Without Servier

GeNeuroĀ announced it has reacquired from Servier the worldwide rights to commercialize and develop the investigational humanized antibodyĀ GNbAC1Ā for the treatment of multiple sclerosis (MS). The decision came after Servier, a European company which, together with GeNeuro, developed the GNbAC1 program, declined to continue developing the therapy due to…

Ibudilast Slows Brain Shrinkage 48% in Progressive MS Patients in Phase 2 Trial; Lead Researcher Says Finding is ‘Remarkable’

Progressive multiple sclerosis patients ā€” with primary or secondary progressive disease ā€” treated with high doses of oralĀ ibudilastĀ in a Phase 2 clinical trial showed a 48 percent slowing in the progression of brain atrophy, or shrinkage, relative to those given a placebo, study data show. What this…